SUBSCRIBE
SUBSCRIBE
News   Drug Development

Cosmo Pharmaceuticals S.p.A.'s Rifamycin Meets Target in Diarrhea Trial

July 5, 2007 | 
1 min read
ZURICH, July 4 (Reuters) - Italy's Cosmo Pharmaceuticals said on Wednesday a mid- to late-stage trial of its Rifamycin drug in infectious diarrhoea had met its primary objective, boosting the biotech company's shares.
Clinical research Phase II Phase III Europe
MORE ON THIS TOPIC
Metal pipe with empty flange covering the end. A PVC pipe with metal joins and flanges with bolts.
Opinion
Evolving Market Pressures Force Biopharma Companies to Cut Assets Early
May 21, 2025
 · 
5 min read
 · 
Michael N. Abrams
Abstract colorful DNA helix held by two hands, symbolizing genetics, biology, and advancements in medical research. Conceptual art design. Concept of medicine, treatment, health care, medical science
Rare diseases
CRISPR Success in Single Baby Highlights Rare Disease ‘Crisis’
May 20, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
Modern collage with human heart and hands stock illustration
Cardiovascular disease
Ionis Builds Triglyceride-Lowering Case for RNA-Targeting Tryngolza
May 20, 2025
 · 
2 min read
 · 
Tristan Manalac
US Measles Outbreak and Increase in infection cases concept as a rising deadly outbreak disease and viral illness as a contagious chickenpox or a skin rash.
Policy
The Memory Gap: How Forgotten Diseases Are Making a Dangerous Comeback
May 19, 2025
 · 
6 min read
 · 
Lori Ellis